Cutera (NASDAQ:CUTR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Cutera (NASDAQ:CUTR – Get Rating) in a research report report published on Thursday. The brokerage issued a sell rating on the medical device company’s stock.

Other research analysts have also issued reports about the company. Maxim Group lowered their price objective on Cutera from $55.00 to $50.00 in a research report on Wednesday, March 1st. Stephens lowered their price objective on Cutera from $78.00 to $68.00 and set an overweight rating for the company in a research report on Wednesday, December 28th. Cantor Fitzgerald downgraded Cutera from an overweight rating to a neutral rating and reduced their target price for the company from $85.00 to $33.00 in a research note on Wednesday, January 11th. Finally, William Blair started coverage on Cutera in a research note on Tuesday, January 31st. They issued a market perform rating for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Hold and an average price target of $55.20.

Cutera Stock Performance

Shares of CUTR stock traded down $3.49 during mid-day trading on Thursday, hitting $24.36. The company’s stock had a trading volume of 1,826,110 shares, compared to its average volume of 468,591. The company’s fifty day simple moving average is $32.58 and its 200-day simple moving average is $41.05. Cutera has a 52 week low of $23.48 and a 52 week high of $74.38. The company has a debt-to-equity ratio of 19.38, a quick ratio of 3.66 and a current ratio of 4.26.

Cutera (NASDAQ:CUTR – Get Rating) last posted its quarterly earnings data on Tuesday, February 28th. The medical device company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.09). Cutera had a negative return on equity of 489.05% and a negative net margin of 32.62%. The business had revenue of $67.40 million during the quarter, compared to the consensus estimate of $69.52 million. During the same period last year, the business posted ($0.22) earnings per share. The business’s revenue was up 2.7% on a year-over-year basis. On average, equities research analysts forecast that Cutera will post -1.37 earnings per share for the current year.

Institutional Trading of Cutera

Large investors have recently made changes to their positions in the company. Quantbot Technologies LP acquired a new stake in shares of Cutera in the 3rd quarter valued at about $151,000. Kent Lake Capital LLC acquired a new position in Cutera during the 3rd quarter valued at about $736,000. Eagle Asset Management Inc. boosted its stake in Cutera by 42.7% during the 3rd quarter. Eagle Asset Management Inc. now owns 628,414 shares of the medical device company’s stock valued at $28,655,000 after purchasing an additional 188,103 shares during the last quarter. EVR Research LP boosted its stake in Cutera by 45.4% during the 3rd quarter. EVR Research LP now owns 400,000 shares of the medical device company’s stock valued at $18,240,000 after purchasing an additional 124,983 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in Cutera by 808.1% during the 2nd quarter. Point72 Asset Management L.P. now owns 710,900 shares of the medical device company’s stock valued at $26,659,000 after purchasing an additional 632,612 shares during the last quarter.

About Cutera

(Get Rating)

Cutera, Inc engages in the provision of laser and energy-based aesthetic systems for practitioners. It operates through the following segments: United States, Japan, Asia excluding Japan, Europe, and Rest of the World. Its products include enlighten, excel HR, excel V+, secret Pro, Juliet, secret RF, and xeo.